ERBB2 and gastric carcinoma: Genetic alterations, which in cancer cells magnify mitogenic signalling and are a cause of aggressive disease and resistance to therapies, include amplification of the ErbB2 (also known as HER/neu, for human epidermal growth factor receptor 2) gene, present in many types of cancer and frequent in breast, ovarian and stomach carcinomas [1].